ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 49 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2020. The put-call ratio across all filers is 0.01 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $998,194 | -11.7% | 491,721 | 0.0% | 0.02% | -4.0% |
| Q2 2023 | $1,130,958 | -40.2% | 491,721 | -21.2% | 0.02% | -35.9% |
| Q1 2023 | $1,890,681 | +13.9% | 623,987 | -12.4% | 0.04% | +2.6% |
| Q4 2022 | $1,660,514 | +13.3% | 712,667 | -7.1% | 0.04% | +2.7% |
| Q3 2022 | $1,466,000 | -2.1% | 767,400 | +39.0% | 0.04% | -5.1% |
| Q2 2022 | $1,497,000 | +2.4% | 552,268 | +12.6% | 0.04% | +14.7% |
| Q1 2022 | $1,462,000 | -18.0% | 490,623 | +7.0% | 0.03% | -19.0% |
| Q4 2021 | $1,784,000 | +11.6% | 458,642 | +23.1% | 0.04% | -4.5% |
| Q3 2021 | $1,598,000 | +778.0% | 372,700 | +521.2% | 0.04% | +633.3% |
| Q2 2021 | $182,000 | +26.4% | 60,000 | +38.8% | 0.01% | +20.0% |
| Q1 2021 | $144,000 | -14.3% | 43,218 | -8.6% | 0.01% | -16.7% |
| Q4 2020 | $168,000 | +309.8% | 47,280 | +257.7% | 0.01% | +200.0% |
| Q3 2020 | $41,000 | -30.5% | 13,218 | -37.8% | 0.00% | -60.0% |
| Q4 2019 | $59,000 | -83.1% | 21,261 | -55.7% | 0.01% | -83.3% |
| Q2 2018 | $350,000 | – | 48,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Whitefort Capital Management, LP | 11,895,477 | $24,147,818 | 12.66% |
| Two Seas Capital LP | 8,280,818 | $16,810,061 | 3.38% |
| FourWorld Capital Management LLC | 1,341,907 | $2,724,071 | 0.51% |
| Tejara Capital Ltd | 180,077 | $365,556 | 0.21% |
| Woodline Partners LP | 4,719,903 | $9,581,403 | 0.11% |
| Hudson Bay Capital Management LP | 8,299,808 | $16,848,610 | 0.07% |
| Kepos Capital LP | 155,691 | $316 | 0.06% |
| Virtus ETF Advisers LLC | 40,040 | $81,281 | 0.05% |
| Centiva Capital, LP | 1,071,705 | $2,175,561 | 0.05% |
| Kades & Cheifetz LLC | 20,000 | $40,600 | 0.03% |